CVE-2026-94033 SourceCodester CVE debrief

Who should care

Defenders responsible for SourceCodester Drug Recommendation System 1.0 deployments should assess exposure and prioritize verification and remediation. This includes operators, platform administrators, vulnerability management teams, and security teams who need to verify the presence of this vulnerability, assess exposure, and prioritize patching or applying mitigations.

Why it matters

Defenders should care about CVE-2026-94033 because it is a cross-site scripting vulnerability in SourceCodester Drug Recommendation System 1.0 that can be exploited remotely. The vulnerability affects the User Management component, specifically the /drug_recommender/Admin/add_user file. Defenders responsible for deployments of this system should verify the presence of this vulnerability, assess exposure, and prioritize patching or applying mitigations. Evidence on exploitation and remediation is limited, requiring verification from official sources.

• Verify potential remote attacks
• Assess exposure in SourceCodester Drug Recommendation System 1.0 deployments
• Prioritize patching or mitigations for vulnerable systems

Technical summary

A cross-site scripting vulnerability exists in the /drug_recommender/Admin/add_user file of the SourceCodester Drug Recommendation System 1.0. The vulnerability is triggered by manipulating the txtname, txtemail, or txtpassword arguments. This vulnerability affects unknown code of the file and can be exploited remotely. The exploit has been disclosed to the public and may be used. Defenders should prioritize verifying the presence of this vulnerability in their systems and applying patches or mitigations as available.

Defensive priority

Defenders should prioritize verifying the presence of this vulnerability in their systems and applying patches or mitigations as available.

Recommended defensive actions

• Verify the presence of this vulnerability in SourceCodester Drug Recommendation System 1.0
• Apply patches or mitigations as available
• Monitor for potential remote attacks
• Review compensating controls for exposed systems while remediation is scheduled and verified
• Check relevant monitoring, detection, and logs for exposed assets that need extra review
• Track exceptions, retest remediated assets, and close the item only after evidence is documented
• Confirm whether affected product deployments exist in managed environments and assign an owner for follow-up

Evidence notes

The CVE record and NVD entry provide information on the vulnerability, but details on affected versions, exploitation, and remediation are limited. Defenders should verify the presence of this vulnerability in SourceCodester Drug Recommendation System 1.0 deployments and assess exposure. Evidence on exploitation and remediation is limited, requiring verification from official sources and careful review of available information.

Sources and references

Methodology and review provenance

AI-assisted synthesis based on stored public vulnerability evidence. System validation, approval state, and publication status do not by themselves establish human review of this revision. PatchSiren helps prioritize defensive review and does not prove exposure or remediation on any system.